Predictors of mortality and morbidity in patients with chronic heart failure

被引:732
|
作者
Pocock, SJ
Wang, DL
Pfeffer, MA
Yusuf, S
McMurray, JJV
Swedberg, KB
Östergren, J
Michelson, EL
Pieper, KS
Granger, CB
机构
[1] London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HT, England
[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[3] Hamilton Hlth Sci, Hamilton, ON, Canada
[4] McMaster Univ, Hamilton, ON, Canada
[5] Univ Glasgow, Glasgow, Lanark, Scotland
[6] Sahlgrenska Univ Hosp, Gothenburg, Sweden
[7] Karolinska Hosp, S-10401 Stockholm, Sweden
[8] AstraZeneca LP, Wilmington, DE USA
[9] Duke Clin Res Inst, Durham, NC USA
关键词
chronic heart failure; clinical trial database; risk score; prognostic models; mortality; hospitalization;
D O I
10.1093/eurheartj/ehi555
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We aimed to develop prognostic models for patients with chronic heart failure (CHF). Methods and results We evaluated data from 7599 patients in the CHARM programme with CHF with and without left ventricular systolic dysfunction. Multi-variable Cox regression models were developed using baseline candidate variables to predict all-cause mortality (n=1831 deaths) and the composite of cardiovascular (CV) death and heart failure (HF) hospitalization (n=2460 patients with events). Final models included 21 predictor variables for CV death/HF hospitalization and for death. The three most powerful predictors were older age (beginning > 60 years), diabetes, and lower left ventricular ejection fraction (EF) (beginning < 45%). Other independent predictors that increased risk included higher NYHA class, cardiomegaly, prior HF hospitalization, male sex, lower body mass index, and lower diastolic blood pressure. The model accurately stratified actual 2-year mortality from 2.5 to 44% for the lowest to highest deciles of predicted risk. Conclusion In a large contemporary CHF population, including patients with preserved and decreased left ventricular systolic function, routine clinical variables can discriminate risk regardless of EF. Diabetes was found to be a surprisingly strong independent predictor. These models can stratify risk and help define how patient characteristics relate to clinical course.
引用
收藏
页码:65 / 75
页数:11
相关论文
共 50 条
  • [1] Antibodies to oxidized LDL as predictors of morbidity and mortality in patients with chronic heart failure
    George, J.
    Charach, G.
    Keren, G. K.
    [J]. EUROPEAN HEART JOURNAL, 2007, 28 : 553 - 553
  • [2] Antibodies to Oxidized LDL as Predictors of Morbidity and Mortality in Patients With Chronic Heart Failure
    Charach, Gideon
    George, Jacob
    Afek, Arnon
    Wexler, Dov
    Sheps, David
    Keren, Gad
    Rubinstein, Ardon
    [J]. JOURNAL OF CARDIAC FAILURE, 2009, 15 (09) : 770 - 774
  • [3] Predictors of Development in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
    Preiss, David
    Zetterstrand, Sofia
    McMurray, John J. V.
    Ostergren, Jan
    Michelson, Eric L.
    Granger, Christopher B.
    Yusuf, Salim
    Swedberg, Karl
    Pfeffer, Marc A.
    Gerstein, Hertzel C.
    Sattar, Naveed
    [J]. DIABETES CARE, 2009, 32 (05) : 915 - 920
  • [4] Predictors of Mortality and Morbidity in Patients With Chronic Heart Failure - Analysis of Red-HF Trial
    Anand, Inder S.
    Yu, Changhong
    Pfeffer, Marc A.
    McMurray, John J.
    Desai, Akshay S.
    Solomon, Scott D.
    Veldhuisen, Dirk J.
    Cheng, Sunfa
    Olson, Kurt
    Maggioni, Aldo P.
    Swedberg, Karl
    Young, James B.
    [J]. CIRCULATION, 2014, 130
  • [5] The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
    Packer, M
    Bristow, MR
    Cohn, JN
    Colucci, WS
    Fowler, MB
    Gilbert, EM
    Shusterman, NH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (21): : 1349 - 1355
  • [6] Effect of carvedilol on mortality and morbidity in patients with chronic heart failure
    Willerson, JT
    [J]. CIRCULATION, 1996, 94 (04) : 592 - 592
  • [7] Markers of Oxidative Damage and Antioxidant Enzyme Activities as Predictors of Morbidity and Mortality in Patients With Chronic Heart Failure
    Radovanovic, Slavica
    Savic-Radojevic, Ana
    Pljesa-Ercegovac, Marija
    Djukic, Tatjana
    Suvakov, Sonja
    Krotin, Mirjana
    Simic, Dragan V.
    Matic, Marija
    Radojicic, Zoran
    Pekmezovic, Tatjana
    Simic, Tatjana
    [J]. JOURNAL OF CARDIAC FAILURE, 2012, 18 (06) : 493 - 501
  • [8] PSYCHOSOCIAL AND BIOMEDICAL PREDICTORS OF MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE
    Shen, Biing-Jiun
    Maeda, Uta
    Eisenberg, Stacy
    Mallon, Stephen
    [J]. ANNALS OF BEHAVIORAL MEDICINE, 2012, 43 : S285 - S285
  • [9] The Role of Serum VCAM-1 and TNF-α as Predictors of Mortality and Morbidity in Patients with Chronic Heart Failure
    Savic-Radojevic, Ana
    Radovanovic, Slavica
    Pekmezovic, Tatjana
    Pljesa-Ercegovac, Marija
    Simic, Dragan
    Djukic, Tatjana
    Matic, Marija
    Simic, Tatjana
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2013, 27 (02) : 105 - 112
  • [10] Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?
    Cooper, Lauren B.
    Mentz, Robert J.
    Stevens, Susanna R.
    Felker, G. Michael
    Lombardi, Carlo
    Metra, Marco
    Stevenson, Lynne W.
    O'Connor, Christopher M.
    Milano, Carmelo A.
    Patel, Cretan B.
    Rogers, Joseph G.
    [J]. JOURNAL OF CARDIAC FAILURE, 2016, 22 (03) : 182 - 189